2001至2005年全球处方药销售和新药研发趋势的分析  

Analysis of Trends of Human Prescription Drug Global Sales and Research and Development of New Drugs

作　　者：吴卫星[1] 杨宁[1] 王小宁[2] 

机构地区：[1]军事医学科学院输血医学研究所,北京100850 [2]华南理工大学生物科学与工程学院,广东广州510640

出　　处：《生物技术通讯》2006年第4期605-608,共4页Letters in Biotechnology

摘　　要：分析处方药市场动态和研发趋势将对我国“十一五”生物医药发展战略的确立提供有意义的参考。全球人用处方药市场近5年发展迅速,其销售额连续突破了4000亿、5000亿和6000亿美元等“多零”关节点,已经成为21世纪经济快车的重要引擎之一。世界50强和10强制药企业销售额合计分别占总额的70%～78%和42%～58%;2005年,50强和10强的研发投入分别约为750亿美元和450亿美元。年销售额超过10亿美元的“重磅炸弹”总数为94个,降血脂药物销售稳定地排在首位,抗肿瘤药物近2年增长最快,生物制品连续2年增长率大于17%。新批上市药物呈现了下降趋势。Analyzing and understanding the marketing dynamics of human prescription drugs and trends of R＆D of new drugs provide comprehensive information on strategic decision-making of biomedicines for the next five years in China. Markets of human prescription drugs have been developing very fast during the last five years. Total sales have exceeded multi-zero points of 400, 500 and 600 billion US dollars, and the market has become one of the important engines of 21st century economic train. The world＇s top 50 and top 10 pharmaceutical companies have gained 70%-78% and 42%- 58% of the market share respectively. The top 50 and top 10 invested 75 and 45 billion US dollars respectively in 2005. There are 94 blockbusters, of which cholesterol and triglyceride reducers have ranked no.1. Anti-cancer drugs have increased at the fastest rate in the last two years, while biologics has grown by more than 17% for two straight years. The number of newly-launched drugs has decreased.

关 键 词：处方药 全球销售 新药研发 发展战略 

分 类 号：F407.7[经济管理—产业经济]